FDA cited BEO Pharma for manufacturing quality violations, including missing identity testing of high-risk drug ingredients and releasing a batch before microbial testing.
What happened
FDA inspected BEO Pharma's Brooksville, Florida drug manufacturing facility from October 16 to November 4, 2024. FDA found that the company did not adequately test incoming components, including high-risk ingredients for diethylene glycol (DEG) and ethylene glycol (EG); released a batch before complete microbial testing; lacked raw material reserve samples; had inadequate process validation and water monitoring; and lacked suitable microbiological test methods. FDA said the company's November 25, 2024 response was inadequate.
What FDA found
The company did not test each incoming component lot for identity and other quality attributes, and did not establish that its suppliers' test results were reliable.
21 CFR 211.84(d)(1) and 211.84(d)(2)The company did not perform identity testing on each shipment of each lot of high-risk components to check for diethylene glycol (DEG) or ethylene glycol (EG) contamination.
21 CFR 211.84(d)(1) and 211.84(d)(2)The quality unit released and shipped a batch before complete finished-product microbial testing was received.
21 CFR 211.22(a), 211.22(d), and 211.165(a)The company did not keep reserve samples of incoming raw materials, including active ingredients and high-risk components.
21 CFR 211.22(a) and 211.22(d)The company did not adequately validate its OTC liquid drug manufacturing processes before commercial distribution and did not sufficiently maintain and monitor its water system.
21 CFR 211.100(a)The company did not establish that its microbiological test methods were suitable, because the protocols lacked a final step to confirm recovered microorganisms.
21 CFR 211.160(b)
What FDA wants
FDA tells BEO Pharma to correct the violations promptly and respond in writing within 15 working days with corrective actions, risk assessments, validation and testing plans, and a review by a qualified current good manufacturing practice (CGMP) consultant.
Who should pay attention
- brands and retailers that buy OTC liquid drugs from this contract manufacturer
- companies sourcing high-risk ingredients such as glycerin or propylene glycol
- quality teams relying on supplier certificates of analysis
This is a summary. Read the original letter on fda.gov.